Indazole compounds as CCR1 receptor antagonists
US8008327B2 · kind B2 · utility
6Cited by
30References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2009 |
| Grant date | Aug 30, 2011 |
| Priority date | — |
| Expiry date | Apr 23, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.